Conference Coverage
Radiopeptide therapy sparks unheard of PFS in midgut neuroendocrine tumors
The experimental radiopeptide therapy 177Lu-Dotatate looks poised to become a new treatment option for patients with midgut neuroendocrine tumors...
The safety profile was consistent with the known profile of everolimus, he said. In the everolimus arm, the most common drug-related adverse events of any grade were stomatitis (63%), diarrhea (31%), fatigue (31%), and infections (29%). Common grade 3/4 events were stomatitis (9%), diarrhea (7%), infections (7%), and fatigue (3%).
Dr. Peter Naredi, scientific cochair of the congress, commented that this year’s meeting is particularly exciting for clinicians treating patients with neuroendocrine tumors because two trials, RADIANT-4 and NETTER-1 both show positive results.
On Twitter @pwendl
